Key statistics
On Monday, BioMarin Pharmaceutical Inc (0HNC:LSE) closed at 59.90, 19.52% above the 52 week low of 50.12 set on Dec 19, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 59.90 |
| Low | 59.90 |
| Bid | -- |
| Offer | -- |
| Previous close | 63.03 |
| Average volume | 2.17k |
|---|---|
| Shares outstanding | 192.32m |
| Free float | 190.76m |
| P/E (TTM) | 34.65 |
| Market cap | 11.87bn USD |
| EPS (TTM) | 1.78 USD |
Data delayed at least 20 minutes, as of Mar 02 2026 18:53 GMT.
More ▼
Press releases
- U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
- BioMarin to Participate in Four Upcoming Investor Conferences in March
- BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
- Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight
- BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
- BioMarin Announces Closing of Private Offering of Senior Notes
- BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
- BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer
- BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
More ▼
